CS/BSE/NSE/PR/2018-2019
May 7, 2018

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Stock Code: SUVEN - EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: 530239

Dear Sir/Madam,

Sub: Press Release

With reference to above subject, please find enclosed Press Release of our company titled **"SUVEN's Pashamylaram's Unit Successfully completes US FDA Inspection"**

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**

K. Hanumantha Rao
Company Secretary

News Release

SUVEN's Pashamylaram's Unit Successfully completes US FDA Inspection

HYDERABAD, INDIA (May 7, 2018) – Suven Life Sciences Limited an ISO 9001, ISO 14001 and OHSAS 18001 company has undergone **US FDA renewal** inspection at their facility in **Pashamylaram** near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs), intermediates and formulations under cGMP during **Feb 5th through 15th 2018**.

Based on this FDA inspection and the review thereafter, the facility is considered to be in an acceptable state of compliance with regards to Current Good Manufacturing Processes (CGMP) and the agency has determined that the inspection classification of this facility is "no action indicated ("NAI"). Also FDA has concluded that the inspection is "closed" under 21CFR20.64 (d) (3) and the agency has issued an Establishment Inspection Report (EIR) for Suven facility at Pashamylaram.

So far Suven Life Sciences has filed 19 DMF's and 5 ANDA's from this facility which is FDA complaint under cGMP and continued after renewal inspection.

Suven Life Sciences is a Hyderabad based biopharmaceutical company, a pioneer in Contract Research and Manufacturing Services **(CRAMS) since 1995 and Drug Discovery and Development** since 2005.

Suven's Drug Discovery program is focused on discovering, developing and commercializing novel pharmaceutical products, which are **first in class or best in class CNS therapies** through the use of GPCR targets. **Suven has 4 clinical stage compounds**, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 undergoing SUVN-911.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as Alzheimer's disease, ADHD, dementia, depression, Huntington's disease, Parkinson's disease, pain and sleep disorders.

For more information please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited
Registered Office: 8-2-334 l SDE Serene Chambers l 6th Floor, Road No.5 l Avenue 7
Banjara Hills l Hyderabad – 500 034 l Telangana l India l CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com